Literature DB >> 7983643

Outcome in rheumatoid arthritis. A 1985 inception cohort study.

M E Suarez-Almazor1, C L Soskolne, L D Saunders, A S Russell.   

Abstract

OBJECTIVE: Our purpose was to describe the clinical status and outcome of a 1985 inception cohort of patients with rheumatoid arthritis (RA), retrospectively established.
METHODS: All patients with RA in Edmonton, with a possible onset of disease in 1985, and who consulted a rheumatologist at any time from January, 1985 through June, 1991 were considered for inclusion in the cohort. Patients were contacted and assessed between August, 1991 and June, 1992. The following indices were used as outcome measures: joint counts, radiological scores of hand radiographs and the modified Health Assessment Questionnaire for activities of daily living (MHAQ).
RESULTS: One hundred and twenty eight patients were included in the cohort (70% were women; age at onset was 52 +/- 13 years). At the time of the assessment, 41 patients (32%) had no articular swelling. Twenty-nine patients (23%) had a radiological score of 0, and 39 (31%) had no erosions. The mean MHAQ score was 0.49 +/- 0.47; 39 patients (31%) had a score of 0 (normal function). Rheumatoid factors and nodules were related to more severe outcomes. Sex, age at onset and mode of onset were not related to prognosis. Most patients had received 2nd line therapy within the first 3 years of RA.
CONCLUSION: Our results suggest that the prognosis of RA after 6-7 years of disease is not as ominous as has been suggested by others. Since most of the previous studies have been conducted in prevalent cases attending tertiary centers, a selection bias may be responsible for some of these results. Since these patients were treated early in the course of the disease, the beneficial effects of prompt 2nd line therapy cannot be excluded.

Entities:  

Mesh:

Year:  1994        PMID: 7983643

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

1.  Severity of rheumatoid arthritis: the SEVERA study.

Authors:  Rafic Baddoura; Souha Haddad; Hassane Awada; Abdel Fattah Al-Masri; Georges Merheb; Said Attoui; Jad Okais; Jamil Messayke; Fadi Ghandour
Journal:  Clin Rheumatol       Date:  2005-12-15       Impact factor: 2.980

2.  Disease activity and functional changes of RA patients receiving different DMARDs in clinical practice.

Authors:  Manathip Osiri; Utis Deesomchok; Peter Tugwell
Journal:  Clin Rheumatol       Date:  2005-12-20       Impact factor: 2.980

3.  A simple algorithm to predict the development of radiological erosions in patients with early rheumatoid arthritis: prospective cohort study.

Authors:  P Brennan; B Harrison; E Barrett; K Chakravarty; D Scott; A Silman; D Symmons
Journal:  BMJ       Date:  1996-08-24

Review 4.  Criteria for TNF-targeted therapy in rheumatoid arthritis: estimates of the number of patients potentially eligible.

Authors:  T K Kvien; T Uhlig; I S Kristiansen
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Predicting factors for severity of rheumatoid arthritis: a prospective multicenter cohort study of 172 patients over 3 years.

Authors:  E Wagner; K Ammer; G Kolarz; I Krajnc; E Palkonyai; O Scherak; C Schödl; F Singer; P Temesvari; A Wottawa
Journal:  Rheumatol Int       Date:  2007-04-11       Impact factor: 2.631

6.  Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis.

Authors:  R Goldbach-Mansky; J M Lee; J M Hoxworth; D Smith; P Duray; R H Schumacher; C H Yarboro; J Klippel; D Kleiner; H S El-Gabalawy
Journal:  Arthritis Res       Date:  2000-02-09

7.  Salivary Microbiota and Host-Inflammatory Responses in Periodontitis Affected Individuals With and Without Rheumatoid Arthritis.

Authors:  Kaja Eriksson; Anna Lundmark; Luis F Delgado; Yue O O Hu; Guozhong Fei; Linkiat Lee; Carina Fei; Anca I Catrina; Leif Jansson; Anders F Andersson; Tülay Yucel-Lindberg
Journal:  Front Cell Infect Microbiol       Date:  2022-03-14       Impact factor: 5.293

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.